NCT00240565View on ClinicalTrials.gov

Tositumomab And Iodine I 131-Tositumomab In Patients With Relapsed Indolent Non-Hodgkin's Lymphoma

PHASE2CompletedINTERVENTIONAL
Enrollment

93

Participants

Timeline

Start Date

April 30, 2004

Primary Completion Date

February 28, 2007

Study Completion Date

September 30, 2011

Conditions
Lymphoma, Non-Hodgkin
Interventions
DRUG

Tositumomab 450 mg

Unlabeled TST

DRUG

Tositumomab 35 mg

TST labeled with 185 megaBecqueral (mbq) of iodine 131

Trial Locations (11)

T2N 4N2

GSK Investigational Site, Calgary

T6G 1Z2

GSK Investigational Site, Edmonton

B3H 2Y9

GSK Investigational Site, Halifax

L8V 5C2

GSK Investigational Site, Hamilton

K1H 8L6

GSK Investigational Site, Ottawa

M4N 3M5

GSK Investigational Site, Toronto

M5G 2M9

GSK Investigational Site, Toronto

H2L 4M1

GSK Investigational Site, Montreal

H4J 1C5

GSK Investigational Site, Montreal

G1R 2J6

GSK Investigational Site, Québec

G1S 4L8

GSK Investigational Site, Québec

Sponsors

Lead Sponsor

GlaxoSmithKline
All Listed Sponsors
lead

GlaxoSmithKline

INDUSTRY